BEATRICE CAVALLUZZO

Dr. BEATRICE CAVALLUZZO

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2022 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
CRConcetta Ragone
Concetta Ragone
CMCarmen Manolio
Carmen Manolio
AMAngela Mauriello
Angela Mauriello
BCBEATRICE CAVALLUZZO
BEATRICE CAVALLUZZO
Franco M BuonaguroFranco M Buonaguro
Franco M Buonaguro
Luigi BuonaguroLuigi Buonaguro
Luigi Buonaguro
Background: The gut microbiota profile is unique for each individual and are composed by different bacteria species according to individual birth-to-infant transitions. In the last years, the local and systemic effects of microbiota on cancer onset, progression and response to treatments, such as immunotherapies, has been extensively described. Here we offer a new perspective, proposing a role for the microbiota based on the molecular mimicry of tumor associated antigens by microbiome-associated antigens. Methods: In the present study we looked for homology between published TAAs and non-self microbiota-derived epitopes. Blast search for sequence homology was combined with extensive bioinformatics analyses. Results: Several evidences for homology between TAAs and microbiota-derived antigens have been found. Strikingly, three cases of 100% homology between the paired sequences has been identified. The predicted average affinity to HLA molecules of microbiota-derived antigens is very high (< 100 nM). The structural conformation of the microbiota-derived epitopes is, in general, highly similar to the corresponding TAA. In some cases, it is identical and contact areas with both HLA and TCR chains are indistinguishable. Moreover, the spatial conformation of TCR-facing residues can be identical in paired TAA and microbiota-derived epitopes, with exactly the same values of planar as well as dihedral angles. Conclusions: The data reported in the present study show for the first time the high homology in the linear sequence as well as in structure and conformation between TAAs and peptides derived from microbiota species of the Firmicutes and the Bacteroidetes phyla, which together account for 90% of gut microbiota. Cross-reacting CD8+ T cell responses are very likely induced. Therefore, the anti-microbiota T cell memory may turn out to be an anti-cancer T cell memory, able to control the growth of a cancer developed during the lifetime if the expressed TAA is similar to the microbiota epitope. This may ultimately represent a relevant selective advantage for cancer patients and may lead to a novel preventive anti-cancer vaccine strategy.

20 November 2019 in Cancers
Verified
Journal Article
Open access
PDF file
AMAngela Mauriello
Angela Mauriello
RZRoberta Zeuli
Roberta Zeuli
BCBEATRICE CAVALLUZZO
BEATRICE CAVALLUZZO
APAnnacarmen Petrizzo
Annacarmen Petrizzo
Maria Lina TorneselloMaria Lina Tornesello
Maria Lina Tornesello
Luigi BuonaguroLuigi Buonaguro
Luigi Buonaguro
Cancer genome instability leads to accumulation of mutations which may result into tumor-specific mutated “neoantigens”, not be affected by central T-cell tolerance. Such neoantigens are considered the optimal target for the patient’s anti-tumor T cell immunity as well as for personalized cancer immunotherapy strategies. However, only a minor fraction of predicted neoantigens are relevant to the clinical outcome. In the present study, a prediction algorithm was applied using datasets of RNA sequencing from all 377 Hepatocellular carcinoma (HCC) patients available at The Cancer Genome Atlas (TCGA), to predict neoantigens to be presented by each patient’s autologous HLA molecules. Correlation with patients’ survival was performed on the 115 samples for whom the exact date of death was known. A total of 30 samples were used for the training set, and 85 samples were used for the validation sets. Neither the somatic mutations nor the number nor the quality of the predicted neoantigens correlate as single parameter with survival of HCC patients who do not undergo immunotherapy treatment. Furthermore, the preferential presentation of such neoantigens in the context of one of the major histocompatibility complex MHC class I molecules does not have an impact on the survival. On the contrary, the expression of Granzyme A (GZMA) is significantly correlated with survival and, in the context of high GZMA, a direct correlation between number and quality of neoantigens with survival is observed. This is in striking contrast to results described in cancer patients undergoing immunotherapy, in which a strong correlation between Tumor Mutational Burden (TMB), number of predicted neoantigens and survival has been reported.

21 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
APAnnacarmen Petrizzo
Annacarmen Petrizzo
CRConcetta Ragone
Concetta Ragone
BCBEATRICE CAVALLUZZO
BEATRICE CAVALLUZZO
AMAngela Mauriello
Angela Mauriello
CMCarmen Manolio
Carmen Manolio
Luigi BuonaguroLuigi Buonaguro
Luigi Buonaguro
Human endogenous retroviruses (HERVs) derive from ancestral exogenous retroviruses whose genetic material has been integrated in our germline DNA. Several lines of evidence indicate that cancer immunotherapy may benefit from HERV reactivation, which can be induced either by drugs or by cellular changes occurring in tumor cells. Indeed, several studies indicate that HERV proviral DNA can be transcribed either to double-stranded RNA (dsRNA) that is sensed as a “danger signal” by pattern recognition receptors (PRRs), leading to a viral mimicry state, or to mRNA that is translated into proteins that may contribute to the landscape of tumor-specific antigens (TSAs). Alternatively, HERV reactivation is associated with the expression of long noncoding RNAs (lncRNAs). In this review, we will highlight recent findings on HERV reactivation in cancer and its implications for cancer immunotherapy.

28 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
BCBEATRICE CAVALLUZZO
BEATRICE CAVALLUZZO
AMAngela Mauriello
Angela Mauriello
CRConcetta Ragone
Concetta Ragone
CMCarmen Manolio
Carmen Manolio
Maria Lina TorneselloMaria Lina Tornesello
Maria Lina Tornesello
Luigi BuonaguroLuigi Buonaguro
Luigi Buonaguro
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer globally. Indeed, only a few treatments are available, most of which are effective only for the early stages of the disease. Therefore, there is an urgent needing for potential markers for a specifically targeted therapy. Candidate proteins were selected from datasets of The Human Protein Atlas, in order to identify specific tumor-associated proteins overexpressed in HCC samples associated with poor prognosis. Potential epitopes were predicted from such proteins, and homology with peptides derived from viral proteins was assessed. A multiparametric validation was performed, including recognition by PBMCs from HCC-patients and healthy donors, showing a T-cell cross-reactivity with paired epitopes. These results provide novel HCC-specific tumor-associated antigens (TAAs) for immunotherapeutic anti-HCC strategies potentially able to expand pre-existing virus-specific CD8+ T cells with superior anticancer efficacy.

15 October 2022 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
CMCarmen Manolio
Carmen Manolio
CRConcetta Ragone
Concetta Ragone
BCBEATRICE CAVALLUZZO
BEATRICE CAVALLUZZO
AMAngela Mauriello
Angela Mauriello
Maria Lina TorneselloMaria Lina Tornesello
Maria Lina Tornesello
Luigi BuonaguroLuigi Buonaguro
Luigi Buonaguro
Background: People living with HIV/AIDS (PLWHA) show a reduced incidence for three cancer types, namely breast, prostate and colon cancers. In the present study, we assessed whether a molecular mimicry between HIV epitopes and tumor associated antigens and, consequently, a T cell cross-reactivity could provide an explanation for such an epidemiological evidence. Methods: Homology between published TAAs and non-self HIV-derived epitopes have been assessed by BLAST homology. Structural analyses have been performed by bioinformatics tools. Immunological validation of CD8+ T cell cross-reactivity has been evaluated ex vivo by tetramer staining. Findings: Sequence homologies between multiple TAAs and HIV epitopes have been found. High structural similarities between the paired TAAs and HIV epitopes as well as comparable patterns of contact with HLA and TCR α and β chains have been observed. Furthermore, cross-reacting CD8+ T cells have been identified. Interpretation: This is the first study showing a molecular mimicry between HIV antigens an TAAs identified in breast, prostate and colon cancers. Therefore, it is highly reasonable that memory CD8+ T cells elicited during the HIV infection may play a key role in controlling development and progression of such cancers in the PLWHA lifetime. This represents the first demonstration ever that a viral infection may induce a natural “preventive” anti-cancer memory T cells, with highly relevant implications beyond the HIV infection.

21 July 2026 in Translational Insights
Verified
Journal Article
Open access
PDF file
AMAngela Mauriello
Angela Mauriello
BCBEATRICE CAVALLUZZO
BEATRICE CAVALLUZZO
CRConcetta Ragone
Concetta Ragone
BCBiancamaria Cembrola
Biancamaria Cembrola
SMSimona Mangano
Simona Mangano
MTMaria Tagliamonte
Maria Tagliamonte
Background: The identification of broadly shared, highly immunogenic tumor antigens remains a central challenge in cancer vaccine development. Non-canonical tumor peptides (nonC-TPs) arising from the cancer “dark genome” have recently emerged as a highly immunogenic class of tumor antigens with strong potential for off-the-shelf cancer vaccine development. These peptides originate from aberrant transcriptional and translational events involving transposable elements, endogenous retroviruses, untranslated regions, and alternative open reading frames, represent a promising antigen class, as they are absent from normal tissues, largely excluded from thymic selection, and shared across tumor histologies and patients. Molecular mimicry between tumor antigens and viral epitopes has been previously demonstrated for canonical tumor-associated antigens (TAAs), providing a mechanistic basis for cross-reactive anti-tumor immunity mediated by virus-specific memory T cells. This has never been investigated in the nonC-TP landscape of the dark genome. Methods: Starting from the proteogenomic dataset generated by Lozano-Rabella, comprising 65,504 canonical and non-canonical peptides identified in several primary cancer cell lines, we prioritized 244 tumor-exclusive non-canonical nonamers predicted as strong HLA binders using NetMHCpan4.1. Then we focused our analysis on restricted NonC peptides binding four HLA-A allotypes. Homology searches against viral proteomes were performed using BLAST, followed by HLA binding and stability prediction with NetMHCstabpan1.0. Structural modelling and molecular docking analyses were conducted to evaluate conservation of peptide-HLA molecular conformations between nonC peptides and viral homologs. Results: A significant subset of dark genome-derived nonC TPs displayed significant sequence homology with viral epitopes across multiple HLA-A alleles, particularly HLA-A*02:01, HLA-A*03:01, and HLA-A*11:01. Homologous viral sequences were identified from clinically relevant pathogens. The homologous peptides frequently conserved amino acid residues predicted to mediate TCR interaction, supporting the possibility of cross-reactive recognition by pre-existing anti-viral memory CD8+ T cells. Structural modelling further demonstrated highly similar peptide-HLA docking conformations between nonC peptides and their viral counterparts, supporting the potential role of molecular mimicry within the dark immunopeptidome. Conclusions: This study provides the first systematic evidence that dark genome-derived nonC-TPs exhibit molecular mimicry with viral antigens, extending a well-established immunological paradigm to a previously unexplored antigen class. The identified viral-homologous nonC-TPs combine tumor specificity, broad sharing across patients and histologies, and potential recognition by pre-existing virus-specific memory T cells, positioning them as uniquely attractive candidates for next-generation, off-the-shelf cancer vaccines. These findings open a new dimension of tumor immunosurveillance and provide a rational framework for the development of immunotherapeutic strategies that exploit the convergence of dark genome biology, molecular mimicry, and viral mimicry.